Resources

TAP was employed to collect capillary blood from 2-month-old infants for antibody tests of RSV and pertussis toxin.

Feasibility of home-based capillary sampling of colorectal cancer marker CEA was demonstrated. TAP was found to be “the most reliable method and is preferred by patients over venipuncture and lancet sampling.” (Erasmus MC)

TAP was employed to demonstrate the feasibility, high patient acceptance, and overall potential of a scalable axSpA hybrid telehealth care pathway.

Use of TAP Point of Care Blood Collection Device for High-Quality Germline Whole Exome Sequencing on Illumina NGS Platforms with the Twist Bioscience Human Core WES Kit

Use of TAP Point of Care Blood Collection Device for Targeted Proteomics with the Olink Target 96 Cardiovascular II Panel Using Proximity Extension Assay Technology.

Use of the TAP Point of Care Blood Collection Device for Biomarker Assessments on the Quanterix Simoa HD-X Platform: Initial Feasibility for Plasma Biomarkers in Alzheimer’s Disease Detection.

Decentralized clinical trials represent a medical research paradigm shift, enhancing patient accessibility and engagement. The future holds increased patient-focused trials driven by regulatory and technological advancements, enabling frequent, less invasive data capture.

TAP® II devices, involves collecting a small blood samples that improves the patient experience, because it’s easier to use than other self-sampling devices.